Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III

Trial Profile

Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Bivalirudin (Primary) ; Fondaparinux sodium; Heparin
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Adverse reactions
  • Acronyms SWITCH-III
  • Most Recent Events

    • 12 Jul 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 12 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top